AHA 2021 | CRAVE: Coffee Safety in Rhythm Disorders

On the one side, caffeine can increase arrythmias or interfere with sleeping, but on the other hand, it helps people feel more energetic and do more physical activity. 

AHA 2021 | CRAVE: Seguridad del café para los trastornos del ritmo

These data contribute to the evidence supporting the fact that people who present, or are at risk of presenting supra ventricular arrythmias or atrial fibrillation might not need to avoid coffee. 

The CRAVE study included 100 young volunteers with no prior arrythmia or heart disease who were instructed to modify caffeine intake habits in two-day blocks. 

Coffee intake did not increase atrial arrythmia, but slightly increased premature ventricular contractions. On the other hand, the day people were allowed to have coffee, they walked 1,000 more steps vs the day coffee was not allowed (p=0.001).

Coffee intake was defined as one standard cup of coffee or an expresso. 

There were no differences between having or not having coffee and the incidence of atrial arrythmia. Also, coffee consumption was associated to fewer supra ventricular tachycardia, but more premature ventricular contractions. 


Read also: AHA 2021 | PALACS: Posterior Left Pericardiotomy Improves Post-Procedural AF.


The day participants were allowed to have coffee, they slept mean 36 minutes less than abstinence day. 

Original Title: The coffee and real-time atrial and ventricular ectopy (CRAVE) trial.

Reference: presentado por Marcus GM durante las sesiones científicas del congreso de la AHA 2021.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

AHA 2025 | DAPT-MVD: Extended DAPT vs. Aspirin Monotherapy After PCI in Multivessel Disease

In patients with multivessel coronary artery disease who remain stable 12 months after drug-eluting stent (DES) stenting, there is uncertainty as to prolonging dual...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...